Skip to main content
Professor Alyn Morice

Professor Alyn Morice

Foundation Chair and Professor of Respiratory Medicine

Faculty and Department

  • Faculty of Health Sciences
  • Hull York Medical School

Summary

Professor Morice is Head of Respiratory Medicine at HYMS, based at the University of Hull. He is also an Honorary Consultant Physician at Hull & East Yorkshire Hospitals NHS Trust. Professor Morice specialises in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specialising in the treatment of asthma and COPD.

The Hull Cough Clinic is one of the largest centres within Europe, with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances, which are incorporated into national and international guideline documents.

Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.

Recent outputs

View more outputs

Journal Article

Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening

Jahanfar, F., Sadofsky, L., Morice, A., & D’Amico, M. (2022). Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening. Membranes, 12(10), Article 954. https://doi.org/10.3390/membranes12100954

Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms

Sykes, D. L., Crooks, M. G., Hart, S. P., Jackson, W., Gallagher, J., & Morice, A. H. (2022). Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respiratory medicine, 202, Article 106985. https://doi.org/10.1016/j.rmed.2022.106985

ATP, an attractive target for the treatment of refractory chronic cough

Zhang, M., Sykes, D. L., Sadofsky, L. R., & Morice, A. H. (2022). ATP, an attractive target for the treatment of refractory chronic cough. Purinergic Signalling, 18, 289-305. https://doi.org/10.1007/s11302-022-09877-z

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

Cotton, S., Devereux, G., Abbas, H., Briggs, A., Campbell, K., Chaudhuri, R., …Lipworth, B. J. (2022). Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23(1), Article 307. https://doi.org/10.1186/s13063-022-06226-8

Chronic Cough in Idiopathic Pulmonary Fibrosis: The Same Difference?

Morice, A. H. (2022). Chronic Cough in Idiopathic Pulmonary Fibrosis: The Same Difference?. American Journal of Respiratory and Critical Care Medicine, 205(9), 985-986. https://doi.org/10.1164/rccm.202201-0083ED

Research interests

Professor Morice specialises in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specialising in the treatment of asthma and COPD.

The Hull Cough Clinic is one of the largest centres within Europe, with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances, which are incorporated into national and international guideline documents.

Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.

Project

Funder

Grant

Started

Status

Project

Two-part, double-blind, placebo-controlled, randomized, parallel-group study - (Part 1) in healthy male volunteers to assess safety and tolerability of ascending repeated oral doses of BAY 1817080 followed (Part 2), two-way crossover administration with four-step dose titration in patients with refractory chronic cough to assess safety, tolerability and efficacy for proof of concept and dose-finding

Funder

Bayer Pharma AG

Grant

£61,101.00

Started

18 July 2018

Status

Complete

Project

AX-8 Clinical Research Collaboration

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£21,285.00

Started

1 June 2016

Status

Complete

Project

BICS: A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease

Funder

NIHR National Institute for Health Research

Grant

£27,108.00

Started

1 June 2017

Status

Complete

Project

VOLCANO-2: A double-blind, placebo controlled study of the efficacy and safety of three doses of Orvepitant in subjects with chronic refractory cough

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£42,493.00

Started

1 August 2017

Status

Complete

Project

Lavolta - A phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£19,047.00

Started

18 May 2014

Status

Complete

Project

OSPREY: An Observational Study of the Phenotype and pRescribing in East Yorkshire and its relevance to the introduction of new prescribing guidelines for airways disease.

Funder

AstraZeneca UK Limited

Grant

£163,413.00

Started

1 October 2016

Status

Complete

Project

Orbit-4: A multi-centre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of Pulmaquin in the management of chronic lung infections with pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis, including 28

Funder

Aradigm Corporation

Grant

£30,144.00

Started

31 October 2014

Status

Complete

Project

TUF: The Utility of FeNo in the differential diagnosis of chronic cough

Funder

Aerocrine AB

Grant

£30,000.00

Started

2 November 2015

Status

Complete

Project

Development Costs: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects

Funder

Afferent Pharmaceuticals Inc

Grant

£62,207.00

Started

5 October 2015

Status

Complete

Project

AFFERENT14: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects

Funder

Afferent Pharmaceuticals Inc

Grant

£140,667.00

Started

5 October 2015

Status

Complete

Project

AFFERENT12: AF219-012: A 12 week Study to assess the Efficacy and tolerability of AF 219 in subjects with treatm

Funder

Afferent Pharmaceuticals Inc

Grant

£22,020.00

Started

1 March 2016

Status

Complete

Project

Proof of Concept study (POC) to investigate the effect of ambroxol hydrochloride (20mg lozenges) on the cough reflex in patients with acute upper respiratory tract infection

Funder

Sanofi Aventis

Grant

£27,342.00

Started

1 October 2017

Status

Complete

Project

RELIEF: A Randomised, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in subjects with Unexplained or Refractory Chronic Cough

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£22,286.00

Started

1 June 2020

Status

Complete

Project

TUSSIX: MTI-110 - A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of Serlopitant for the treatment of refractory chronic cough

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£16,546.00

Started

1 December 2017

Status

Complete

Project

Randomised, double-blind, parallel group. Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£26,613.00

Started

1 January 2021

Status

Complete

Top